GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (FRA:8IY) » Definitions » Accounts Receivable

Yumanity Therapeutics (FRA:8IY) Accounts Receivable : €0.00 Mil (As of Sep. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Yumanity Therapeutics's accounts receivables for the quarter that ended in Sep. 2022 was €0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Yumanity Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2022 was 0.00.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Yumanity Therapeutics's Net-Net Working Capital per share for the quarter that ended in Sep. 2022 was €0.40.


Yumanity Therapeutics Accounts Receivable Historical Data

The historical data trend for Yumanity Therapeutics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yumanity Therapeutics Accounts Receivable Chart

Yumanity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21
Accounts Receivable
- - 4.43

Yumanity Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 4.43 - - -

Yumanity Therapeutics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Yumanity Therapeutics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Yumanity Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2022 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/1.416*91
=0.00

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Yumanity Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Yumanity Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2022 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(8.5+0.75 * 0+0.5 * 0-4.144
-0-0)/10.8565
=0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Yumanity Therapeutics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Yumanity Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Yumanity Therapeutics (FRA:8IY) Business Description

Traded in Other Exchanges
N/A
Address
40 Guest Street, Suite 4410, Boston, MA, USA, 02135
Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Yumanity Therapeutics (FRA:8IY) Headlines

No Headlines